Clinical Trial Update: Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of IBI305 in advanced or recurrent non-squamous non-small cell lung cancer has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBI305 (bevacizumab biosimilar)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: NSCLC | Phase 3 | Status: COMPLETED | Results posted: 2020-12-08